Moderna (NASDAQ: MRNA) announced Thursday that it is seeking the US Food and Drug Administration’s authorization for a second Covid-19 booster shot for people over the age of 18. Amid a surge in Covid cases across the globe, many fear another wave of the pandemic.
The American Pharmaceutical and biotechnology company is asking for an amendment of the FDA’s emergency use authorization regarding its Covid-19 vaccines to include a fourth vaccine dose.
“The request to include adults over 18 years of age was made to provide flexibility for the U.S. Centers for Disease Control and Prevention (CDC) and healthcare providers to determine the appropriate use of an additional booster dose of mRNA-1273, including for those at higher risk of COVID-19 due to age or comorbidities,” the company said in a news release. “This submission is based in part on recently published data generated in the United States and Israel following the emergence of Omicron.”
Moderna’s request includes a larger audience than Pfizer, as it too filed with US regulators for a second booster shot in people over the age of 65. Many US officials, such as Anthony Fauci, have touched on the subject of a fourth shot, primarily for older people and to protect against another surge in cases.
According to the FDA, it will assemble its independent vaccine advisers in April “to have a transparent discussion about considerations for 2022 booster shots, including whether and when those boosters may be needed and for which populations, based on the available data and latest science on circulating or emerging virus variants.”